Spots Global Cancer Trial Database for The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
Official Title: A Phase II Multi-center, Randomized, Open-label Study of Ponatinib in Chinese Patients With Chronic Myeloid Leukemia Who Have Failed Prior TKIs or With T315I Mutation, or Ph+ALL Who Have Failed Prior TKIs or With T315I Mutation
Study ID: NCT04233346
Interventions
Study Description
Brief Summary: This protocol will allow ponatinib with refractory Chronic Myeloid Leukemia or Ph+ Acute Lymphoblastic Leukemia
Detailed Description: The purpose of this study is to determine the safety and efficacy of ponatinib in patients with chronic myeloid leukemia (CML) in chronic phase (CP), accelerated phase (AP) or blast phase (BP) or with Ph positive (Ph+) acute lymphoblastic leukemia (ALL) who either are resistant or intolerant to either dasatinib or nilotinib, or have the T315I mutation.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Anhui Provincial Hospital, Hefei, Anhui, China
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China
Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
Xiangya Hospital Central South University, Changsha, Hunan, China
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Shengjing Hospital of China Medical University, Shenyang, Liaoning, China
Qilu Hospital of Shandong University, Jinan, Shandong, China
Second hospital of Shanxi Medical University, Taiyuan, Shanxi, China
Shenzhen Second People's Hospital, Shenzhen, Shenzhen, China
West China Hospital, Sichuan University, Chengdu, Sichuan, China
The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, Zhejiang, China
1st affiliated hospital, Peking University, Beijing, , China
Hematology Hospital, Chinese Academy of Medical Sciences, Tianjin, , China
Contact Details
Name: Juma Paty, Director
Affiliation: OBRI
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
